Abstract:Abstract Notch receptor-mediated signaling is essential for embryonic development and adult tissue homeostasis by regulating cell proliferation, differentiation and survival. Aberrant Notch signaling is linked to many epithelial cancers and hematological malignancies. For example, activated NOTCH1 mutations are detected in more than 50% of T cell acute lymphoblastic leukemia (T-ALL) patients. Since the constitutive activation of Notch signaling results in leukemic cell transformation and is required for the maintenance of the leukemic phenotype, the Notch pathway is a promising and highly specific molecular therapeutic target for T-ALL. We have previously identified the family of the MAML transcriptional co-activators as essential components of the core Notch transcription activation complex. The prototypic member MAML1 was found to be the major co-activator that regulates NOTCH1 oncogenic activities in leukemic cells. Hence, the modulation of MAML1 expression levels or functional activities is expected to affect Notch-induced leukemic initiation and progression. However, it remains unclear how MAML1 function is regulated. To gain insights into the molecular basis underlying MAML1 function, we undertook the task of identifying cellular factors that interact with MAML1 and characterizing their roles in regulating Notch signaling and Notch-mediated T cell leukemia. Through proteomic studies, we identified DDX5, an ATP-dependent DEAD-box RNA helicase, as a component in the MAML1 protein complex. Given the role of DDX5 as a transcriptional modulator, we reasoned that DDX5 might be a critical regulator of MAML1-mediated Notch target genes transcription. We showed that DDX5 interacts with MAML1 in vitro and in vivo, and is associated with the endogenous Notch1 transcription activation complex through interaction with MAML1. Lentiviral-mediated shRNA knockdown of DDX5 resulted in decreased expression of Notch target signature, along with reduced cell proliferation and survival in leukemic cells that carry activated NOTCH1 mutations. Our findings thus revealed an essential role of DDX5 in promoting efficient Notch-mediated transcription in leukemic cells where the Notch pathway is constitutively activated, suggesting that DDX5 might be critical for Notch-mediated T-ALL pathogenesis and could be a potential new target for modulating the Notch signaling in leukemia. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 3388. doi:10.1158/1538-7445.AM2011-3388

DDX5 Functions As a Tumor Suppressor in Tongue Cancer.

Pan-cancer Analysis of the Prognostic and Immunological Roles of DEAD-box Helicase 5 (DDX5) in Human Tumors

Role of the DEAD-box RNA helicase DDX5 (p68) in cancer DNA repair, immune suppression, cancer metabolic control, virus infection promotion, and human microbiome (microbiota) negative influence

Roles of DDX5 in the Tumorigenesis, Proliferation, Differentiation, Metastasis and Pathway Regulation of Human Malignancies

Decreased Expression of DEAD-Box Helicase 5 Inhibits Esophageal Squamous Cell Carcinomas by Regulating Endoplasmic Reticulum Stress and Autophagy

<i>Dlx5</i> promotes cancer progression through regulation of <i>CCND1</i> in oral squamous cell carcinoma (OSCC)

DDX5 and DDX17—multifaceted proteins in the regulation of tumorigenesis and tumor progression

DEAD-box helicase 27 plays a tumor-promoter role by regulating the stem cell-like activity of human colorectal cancer cells.

DEAD/H-box Helicase 11 is Transcriptionally Activated by Yin Yang-1 and Accelerates Oral Squamous Cell Carcinoma Progression.

DDX5 is a Positive Regulator of Oncogenic NOTCH1 Signaling in T Cell Acute Lymphoblastic Leukemia

DDX5 Promotes Gastric Cancer Cell Proliferation in Vitro and in Vivo Through Mtor Signaling Pathway

Subsite-specific association of DEAD box RNA helicase DDX60 with the development and prognosis of oral squamous cell carcinoma.

A Double-Edged Function Of Ddx3, As An Oncogene Or Tumor Suppressor, In Cancer Progression

The Epigenetic Modifier PRDM5 Functions As a Tumor Suppressor Through Modulating WNT/β-catenin Signaling and is Frequently Silenced in Multiple Tumors.

DDX41 Regulates the Expression and Alternative Splicing of Genes Involved in Tumorigenesis and Immune Response

DDX5 Promotes Hepatocellular Carcinoma Tumorigenesis Via Akt Signaling Pathway.

Knockdown of DEAD-box RNA Helicase 52 (DDX52) Suppresses the Proliferation of Melanoma Cells in Vitro and of Nude Mouse Xenografts by Targeting C-Myc

Upregulated Expression of DDX5 Predicts Recurrence and Poor Prognosis in Breast Cancer.

DDX3 acts as a tumor suppressor in colorectal cancer as loss of DDX3 in advanced cancer promotes tumor progression by activating the MAPK pathway

DDX21 Interacts with WDR5 to Promote Colorectal Cancer Cell Proliferation by Activating CDK1 Expression

Ddx5 Modulates Notch Signaling Via Interaction With The Maml1 Co-Activator And Is Required To Optimal Notch Signaling In Leukemic Cells